Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML

Research output: Contribution to journal › Letter › Research › peer-review

Standard

Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML. / Rapin, N; Porse, B T.

In: Oncogenesis, Vol. 3, e106, 2014, p. 1-5.

Research output: Contribution to journal › Letter › Research › peer-review

Harvard

Rapin, N & Porse, BT 2014, 'Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML', Oncogenesis, vol. 3, e106, pp. 1-5. https://doi.org/10.1038/oncsis.2014.22

APA

Rapin, N., & Porse, B. T. (2014). Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML. Oncogenesis, 3, 1-5. [e106]. https://doi.org/10.1038/oncsis.2014.22

Vancouver

Rapin N, Porse BT. Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML. Oncogenesis. 2014;3:1-5. e106. https://doi.org/10.1038/oncsis.2014.22

Author

Rapin, N ; Porse, B T. / Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML. In: Oncogenesis. 2014 ; Vol. 3. pp. 1-5.

Bibtex

@article{b025dfb36e544eee8150200696c248b6,
title = "Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML",
abstract = "Reciprocal chromosomal translocations are observed in one-third of acute myeloid leukemia (AML) cases. Targeting and understanding the effects of the resulting aberrant oncogenic fusion proteins may help developing drugs against specific leukemic subtypes, as demonstrated earlier by the use of ATRA in acute promyelocytic leukemia. Hematopoietic stem/progenitor (HSPCs) cells transduced with oncogenic fusion genes are regarded as promising in vitromodels of their corresponding AML subtypes. Here, we critically assessed the potential of such in vitro models using an integrative bioinformatics approach. Surprisingly, we found that the gene-expression profiles of CD34+ human HSPCs transformed with the potent oncogenic fusion proteins AML-ETO or MLL-AF9, only weakly resembled those derived from primary AML samples. Hence, our work raises concerns as to the relevance of the use of in vitro transduced cells to study the impact of transcriptional deregulation in human AML.",
author = "N Rapin and Porse, {B T}",
year = "2014",
doi = "10.1038/oncsis.2014.22",
language = "English",
volume = "3",
pages = "1--5",
journal = "Oncogenesis",
issn = "2157-9024",
publisher = "Nature Publishing Group: Open Access Journals - Option B",

}

RIS

TY - JOUR

T1 - Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML

AU - Rapin, N

AU - Porse, B T

PY - 2014

Y1 - 2014

N2 - Reciprocal chromosomal translocations are observed in one-third of acute myeloid leukemia (AML) cases. Targeting and understanding the effects of the resulting aberrant oncogenic fusion proteins may help developing drugs against specific leukemic subtypes, as demonstrated earlier by the use of ATRA in acute promyelocytic leukemia. Hematopoietic stem/progenitor (HSPCs) cells transduced with oncogenic fusion genes are regarded as promising in vitromodels of their corresponding AML subtypes. Here, we critically assessed the potential of such in vitro models using an integrative bioinformatics approach. Surprisingly, we found that the gene-expression profiles of CD34+ human HSPCs transformed with the potent oncogenic fusion proteins AML-ETO or MLL-AF9, only weakly resembled those derived from primary AML samples. Hence, our work raises concerns as to the relevance of the use of in vitro transduced cells to study the impact of transcriptional deregulation in human AML.

AB - Reciprocal chromosomal translocations are observed in one-third of acute myeloid leukemia (AML) cases. Targeting and understanding the effects of the resulting aberrant oncogenic fusion proteins may help developing drugs against specific leukemic subtypes, as demonstrated earlier by the use of ATRA in acute promyelocytic leukemia. Hematopoietic stem/progenitor (HSPCs) cells transduced with oncogenic fusion genes are regarded as promising in vitromodels of their corresponding AML subtypes. Here, we critically assessed the potential of such in vitro models using an integrative bioinformatics approach. Surprisingly, we found that the gene-expression profiles of CD34+ human HSPCs transformed with the potent oncogenic fusion proteins AML-ETO or MLL-AF9, only weakly resembled those derived from primary AML samples. Hence, our work raises concerns as to the relevance of the use of in vitro transduced cells to study the impact of transcriptional deregulation in human AML.

U2 - 10.1038/oncsis.2014.22

DO - 10.1038/oncsis.2014.22

M3 - Letter

C2 - 24932908

VL - 3

SP - 1

EP - 5

JO - Oncogenesis

JF - Oncogenesis

SN - 2157-9024

M1 - e106

ER -

ID: 127880531